Skip to main content
GRI logo

GRI Bio, Inc.

GRINASDAQHealthcareBiotechnology

$1.38Today:- (-)1Y −27.84%

As of Oct 16, 2026 close

Market cap
$2.53M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.36$64.12
Volume (live)
-
Avg. volume (3M)
350.87K

GRI Bio (GRI) Key Statistics & Financial Metrics

Complete stock analysis with 60+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Price-Based Ratios

Valuation ratios based on stock price

Price/Tangible Book (mrq)0.25

Enterprise Value Ratios

EV-based valuation multiples

EV/Earnings0.87
EV/FCF0.80

Stock Price

Current price, 52-week range, and moving averages

Current Price$1.38
1-Day Change0.00%
52-Week High$64.12
52-Week Low$1.36
YTD Change−82.14%
1-Year Change−27.84%
50-Day MA$1.87
200-Day MA$2.59
Avg Volume (30 day)350.87K

Analyst Price Targets & Consensus

Wall Street analyst ratings and 12-month price targets (90 days)

Analyst ConsensusBuy
Analyst Count1

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Profit Margins

Profitability margins across income statement

Growth Rates (YoY)

Year-over-year growth metrics

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Source: Market prices and company fundamentals from financial filings. Data as of Oct 16, 2026. Data sources and methodology

Frequently Asked Questions About GRI Bio Statistics

What are the key financial metrics for GRI?

GRI Bio, Inc. (GRI) statistics include 60+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is GRI's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether GRI Bio is overvalued or undervalued.

How do I read GRI's profitability ratios?

GRI Bio's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do GRI's debt ratios indicate?

The financial health section shows GRI Bio's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is GRI's dividend analysis?

The dividend section covers GRI Bio's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.